Phaseline

Companies › Intuitive Surgical

Intuitive Surgical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IS-001 filricianine
Near-infrared fluorescent imaging agent for intraoperative visualization of ureteral struc
–Phase 3Ureter InjuryApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07346066IS-001 filricianinePhase 3Ureter InjuryOtherApr 2027

From the company's SEC filings

Cash and short-term investments of $4.0bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Sound Pharmaceuticals Palvella Therapeutics Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.